Slide 1: Orion Interim Report January–March 2016
Orion Interim Report January─March 2016 27 April 2016 Timo Lappalainen President & CEO
Slide 2: Forward-looking statements
This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of these strat
Slide 3: Year started well as a whole
Year started well as a whole • Net sales similar to comparative period • Operating profit decreased slightly • Specialty Products maintained strong growth • Opening of the market to generic competition is reducing sales of Stalevo in Europe • ODM-104 and ODM-203 into Phase II clinical trials • New p
Slide 4: Key figures
Key figures Q1/2015 Q1/2016 Q1/2015 Q1/2016 260 262 0.47 0.45 0.38 0.29 83 80 Net sales, EUR Operating profit, Basic earnings per Cash flow per share million EUR million share, EUR before financial items, EUR +1% -3% -4% -23% 4 27 April 2016 Orion Interim Report January─March 2016
Slide 5: Breakdown of net sales
Breakdown of net sales Group’s net sales in Q1/2016 were EUR 262 million By business division By market area 5% 4% 4% 14% 7% 33% 30% 7% 32% 47% 17% Proprietary Products Specialty Products Animal Health Finland Scandinavia Fermion Other Europe North America Contract manufacturing & other Orion Diagno
Slide 6: Business Reviews
Business Reviews GRIoN Building well-being
Slide 7: Pharmaceuticals business
Pharmaceuticals business Q1/2015 Q1/2016 Net sales split EUR million Q1/16 Q1/15 Change % 245 249 Proprietary Products 88 89 -1% Specialty Products 123 109 +13% Animal Health 18 22 -16% Fermion 11 15 -28% 81 80 Contract manufacturing & other 10 10 -6% • Net sales excluding branded Parkinson’s drugs,
Slide 8: Best-selling pharmaceuticals Q1/2016
Best-selling pharmaceuticals Q1/2016 Net sales Change Product Indication EUR million vs. Q1/15 Parkinson’s disease 33 -23% Asthma, COPD 16 +25% Intensive care sedative 14 +28% Acute decompensated heart 14 +8% failure Rheumatoid arthritis, 12 +319% inflammatory bowel diseases Animal sedatives 7 -1% A
Slide 9: Orion clear market leader in Finland
Orion clear market leader in Finland Finnish human pharmaceuticals Finland’s biggest pharmaceutical market in Q1/2016 companies in Q1/2016 EUR million Wholesale, EUR million 80 70 69 521 60 Orion’s market +2% share 13% 534 50 40 Orion in Finnish human 30 30 24 28 pharmaceuticals market, 24 EUR milli
Slide 10: Specialty Products growing strongly in Scandinavia
Specialty Products growing strongly in Scandinavia Net sales in key market areas in Net sales Change Q1/2016 (EUR million) Q1/2016 vs. TOP 3 Products EUR million Q1/2015 Vs. Scandinavia 12 +319% Q1/15 21 +44% 5 +3% Vs. Finland 5 -7% Q1/15 70 +8% Eastern Vs. Europe & Q1/15 Russia 12 +6% 10 27 April 2
Slide 11: Parkinson's drugs
Parkinson’s drugs 60 Market shares of Orion’s branded Parkinson’s drugs 2015 2014 50 Finland 1) 14% 20% 40 Sweden 1) EUR million 9% 14% 30 Norway 1) 15% 15% Denmark 1) 7% 13% 20 Germany 2) 9% 13% 10 UK 2) 12% 12% 0 United States 2) 3) 2% 2% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2013 2014 2015 16 Ja
Slide 12: Easyhaler product family and Simdax
Easyhaler® product family and Simdax® Simdax 18 16 16 14 14 12 12 EUR million EUR million 10 10 8 8 6 6 4 4 2 2 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2013 2014 2015 16 2013 2014 2015 16 Others Bufomix Easyhaler Simdax 12 27 April 2016 Orion Interim Report
Slide 13: Dexdor intensive care sedative
dexdor® intensive care sedative European sedative market MAT12/2015* Dexdor sales Total market value EUR 525 million (+5%) 16 13% 14 7% 12 10 EUR million 14% 8 66% 6 4 Propofol EUR 347 million (+3%) 2 Midazolam EUR 76 million (+0%) 0 Dexmedetomidine EUR 36 million (+30%) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q
Slide 14: Key clinical pharmaceutical development projects 1/2
Key clinical pharmaceutical development projects 1/2 Project Indication PHASE Registration Easyhaler® budesonide-formoterol 1) Asthma, COPD I II III Registration Easyhaler® salmeterol-fluticasone 2) Asthma, COPD I II III Prostate cancer ODM-201 (androgen receptor inhibitor) 3) (nm-CRPC) I II III Low
Slide 15: Key clinical pharmaceutical development projects 2/2
Key clinical pharmaceutical development projects 2/2 Project Indication PHASE Registration ODM-104 (more effective COMT inhibitor) Parkinson’s disease I II ODM-203 (targeted FGFR+VEGFR inhibitor) Solid tumours I II ODM-204 (CYP17 enzyme and androgen receptor inhibitor) Prostate cancer I ODM-108 (neg
Slide 16: Diagnostics business
Diagnostics business • Net sales decreased mainly due Q1/2015 Q1/2016 to ending of distribution of certain products that had been 16 represented and slowing market 14 growth in China • Operating profit decreased mainly due to decrease in net 4.0 sales and products with lower 2.6 margins accounting f
Slide 17: Outlook for 2016 (unchanged)
Outlook for 2016 (unchanged) Net sales are estimated to be at similar level to 2015 Net sales (net sales were EUR 1,016 million in 2015). Operating profit Operating profit is estimated to exceed EUR 240 million. 17 27 April 2016 Orion Interim Report January─March 2016
Slide 18: Orion Calendar 2016
Orion Calendar 2016 Half-Yearly Report January─June 2016 Tue 19 Jul 2016 Interim Report January─September 2016 Tue 25 Oct 2016 18 27 April 2016 Orion Interim Report January─March 2016
Slide 19: Slide 19